Your browser doesn't support javascript.
loading
SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity.
Neerukonda, Sabari Nath; Vassell, Russell; Lusvarghi, Sabrina; Wang, Richard; Echegaray, Fernando; Bentley, Lisa; Eakin, Ann E; Erlandson, Karl J; Katzelnick, Leah C; Weiss, Carol D; Wang, Wei.
Afiliación
  • Neerukonda SN; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
  • Vassell R; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
  • Lusvarghi S; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
  • Wang R; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
  • Echegaray F; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Bentley L; Office of the Assistance Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC 20201, USA.
  • Eakin AE; Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, MD 20892, USA.
  • Erlandson KJ; Influenza and Emerging Infectious Diseases Division, Biomedical Advanced Research and Development Authority, U.S. Department of Health and Human Services, Washington, DC 20201, USA.
  • Katzelnick LC; Viral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Weiss CD; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
  • Wang W; Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.
Viruses ; 13(12)2021 12 11.
Article en En | MEDLINE | ID: mdl-34960755
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Glicoproteína de la Espiga del Coronavirus / SARS-CoV-2 Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Viruses Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Anticuerpos Neutralizantes / Glicoproteína de la Espiga del Coronavirus / SARS-CoV-2 Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Viruses Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos